小青竜湯(Xiaoqinglong Decoction) - 在研适应症：结膜炎，哮喘，支气管炎_专利_临床

概要

基本信息

药物类型

中药

别名

OHSUGI Shoseiryuto Extract Granules、オースギ小青竜湯エキスＧ

+ [3]

靶点-

作用机制-

治疗领域

免疫系统疾病感染眼部疾病+ [2]

在研适应症

结膜炎哮喘支气管炎+ [3]

非在研适应症-

原研机构

Ohsugi Pharmaceutical Co., Ltd.

在研机构

Sanwa Shoyaku Co., Ltd.Ohsugi Pharmaceutical Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1986-08-22),

哮喘支气管炎普通感冒+ [2]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与小青竜湯相关的临床试验

ChiCTR2400089407 / RecruitingN/AIIT

Study on the effect and mechanism of Xiaoangtiaojing Decoction on endometrial receptivity of Qi stagnation and dampness stasis PCOS patients

开始日期2024-04-01

申办/合作机构-

ChiCTR2300073544 / SuspendedN/AIIT

Clinical Study on the Mechanism of Xinglou Chengqi Decoction in Treating Acute Ischemic stroke with Phlegm-Heat and Fu-Organ Excess Syndrome

开始日期2024-01-01

申办/合作机构-

NCT01019889 / Completed临床3期IIT

Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection

The purpose of this study is to determine whether Socheongryong-tang (SCRT) and Yeongyopaedok-san (YPS) are effective in the treatment of upper respiratory tract infection.

开始日期2008-09-01

申办/合作机构

Korea Health Industry Development Institute

100 项与小青竜湯相关的临床结果

登录后查看更多信息

100 项与小青竜湯相关的转化医学

登录后查看更多信息

100 项与小青竜湯相关的专利（医药）

登录后查看更多信息

40

项与小青竜湯相关的文献（医药）

2024-11-01·Respiratory Investigation

The association between the use of Shoseiryuto and reduction in intravenous steroid dose among adult inpatients with asthma exacerbation: A national database study in Japan

Article

作者: Hiroki, Matsui ; Aso, Shotaro ; Awano, Nobuyasu ; Ando, Takahiro ; Yokoyama, Akira ; Kage, Hidenori ; Watanabe, Hideaki ; Fushimi, Kiyohide ; Makita, Kosuke ; Yasunaga, Hideo ; Jo, Taisuke ; Saihara-Yamaguchi, Aya ; Urushiyama, Hirokazu

BACKGROUNDShoseiryuto, a Japanese herbal medicine, is used to treat asthma exacerbation; however, the effect of Shoseiryuto in a clinical setting is yet to be elucidated. We aimed to examine the effect of Shoseiryuto for inpatients with asthma exacerbation and the reduction in the total amount of intravenous steroids administered during hospitalization, in-hospital mortality, and length of hospital stay using a national inpatient database in Japan.METHODSUsing data from the Japanese Diagnosis Procedure Combination database (July 2010-March 2022), we identified patients aged ≥18 years who were admitted due to asthma exacerbation. We performed propensity score overlap weighting analyses to estimate the in-hospital outcomes between patients who received Shoseiryuto within 3 days of admission (Shoseiryuto group) and those who did not (control group). The outcomes measured were the dose of intravenous steroids administered, in-hospital mortality, and length of hospital stay for patients alive at discharge.RESULTSAmong 51,459 eligible patients, 131 received Shoseiryuto. In the propensity score overlap weighting analyses, the use of Shoseiryuto was significantly associated with reduced amount of intravenous steroid during hospitalization (67 mg versus 149 mg, 95% confidence interval [CI]: -68 to -92), but was not associated with reduced in-hospital mortality (1.9% versus 3.5%, 95% CI: -28 to 25) or length of hospital stay (17.3 days versus 18.3 days, 95% CI: -4.2 to 2.4).CONCLUSIONSThe use Shoseiryuto in inpatients with asthma exacerbation was significantly associated with reduced steroid use. Our results elucidated the potential role of Shoseiryuto in the treatment of asthma exacerbation.

2024-08-01·Hospital Pharmacy

Cost-effectiveness Analysis of Second-Generation Antihistamine 1 Receptor Blockers and Japanese Kampo Shoseiryuto for Treating Perennial Allergic Rhinitis in Outpatient Settings in Japan

Article

作者: Kashiwabara, Masami ; Egawa, Kei ; Nakagawa, Naoto ; Sasaki, Ayaka

Objectives: Perennial allergic rhinitis (PAR) is common in Japan. Second-generation antihistamines (SGAs) are commonly used for its treatment; however, it remains unclear which SGA is the most cost-effective. Additionally, the pharmacoeconomics of Japanese Kampo shoseiryuto (which was traditionally prescribed to treat PAR in Japan) remains poorly understood. In this study, we aimed to investigate the effectiveness of various SGAs and shoseiryuto for the treatment of PAR in Japanese outpatients, from the healthcare payer’s perspective. Methods: The most cost- and clinically effective SGAs were determined from a list of 6 SGAs (bepotastine, 10 mg; cetirizine, 10 mg; ebastine, 10 mg; epinastine, 20 mg; loratadine, 10 mg; and olopatadine, 5 mg) together with shoseiryuto, using the overall improvement rate through a model-based analysis. The time horizon was 28 days. Costs were determined based on the Medical Fee Index in 2020. Deterministic and probabilistic sensitivity analyses were conducted to address the uncertainty of the base-case results. Results: Overall, bepotastine (10 mg) and ebastine (10 mg) were cost-effective. Shoseiryuto was less cost-effective than ebastine (10 mg) (dominated). Ebastine (10 mg) was the most cost-effective option based on deterministic and probabilistic sensitivity analyses. Conclusions: Ebastine (10 mg) was the most cost-effective treatment strategy for PAR among the agents evaluated in this study. This insight could aid in establishing an appropriate formulary for treating PAR in hospitals and communities.

2024-06-01·Journal of Cellular and Molecular Medicine

Study of the mechanism by which Xiaoyan decoction combined with E7449 regulates tumorigenesis in lung adenocarcinoma

Article

作者: Gu, Lili ; Zheng, Xu ; Han, Yanyan ; Gao, Shan ; Li, Chong ; Lv, Yan

AbstractTNKS is a new target for the treatment of lung adenocarcinoma, the synergistic effects of the TCM compound Xiaoyan decoction and the TNKS inhibitor E7449 in the intervention on TNKS were investigated, and the possible underlying mechanisms involved were clarified. Immunohistochemistry was used to analyse TNKS expression in tumour tissues. The impact of targeting TNKS on cell growth, invasion, apoptosis, key genes and signalling pathways was investigated in tumour cells by Western blotting, rescue experiments, colony formation assays, flow cytometry and label‐free experiments. Tumour xenografts with A549 cells were then transplanted for in vivo study. We found that TNKS high expression was closely related to the advanced tumour stage and tumour size in lung adenocarcinom. After TNKS was knocked down in vitro, the growth, proliferation, migration and invasion were markedly reduced in A549 and H1975 cells. We subsequently applied the Xiaoyan decoction and TNKS inhibitors to intervene in lung adenocarcinoma. Xiaoyan decoction and E7449 suppressed TNKS expression and inhibited adenocarcinoma cell proliferation, migration, invasion and apoptosis in vitro. Proteomic analysis revealed that E7449 treatment may be most closely associated with the classic Wnt/β‐catenin pathway, whereas Xiaoyan decoction treatment may be related to the WNT/PLAN pathway. Xenograft studies confirmed that E7449 or Xiaoyan decoction inhibited lung tumour growth in vivo and attenuated the Wnt signalling pathway in adenocarcinoma. These findings suggest that TNKS is a novel therapeutic target. TCM preparations and small molecule inhibitors are expected to constitute an effective combination strategy.

100 项与小青竜湯相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
结膜炎	日本	Sanwa Shoyaku Co., Ltd.	1986-10-30
哮喘	日本	Ohsugi Pharmaceutical Co., Ltd.	1986-08-22
支气管炎	日本	Ohsugi Pharmaceutical Co., Ltd.	1986-08-22
普通感冒	日本	Ohsugi Pharmaceutical Co., Ltd.	1986-08-22
变应性结膜炎	日本	Ohsugi Pharmaceutical Co., Ltd.	1986-08-22
过敏性鼻炎	日本	Ohsugi Pharmaceutical Co., Ltd.	1986-08-22